# Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

> **NCT02161770** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 30 (actual)

## Conditions studied

- Solid Tumours

## Interventions

- **DRUG:** AZD9291 tablet dosing
- **PROCEDURE:** Pharmacokinetic sampling - AZD9291
- **PROCEDURE:** Pharmacokinetic sampling - AZ5140 and AZ7550

## Key facts

- **NCT ID:** NCT02161770
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-22
- **Primary completion:** 2017-05-16
- **Final completion:** 2017-08-22
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02161770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02161770, "Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02161770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*